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Background: Our objective was to assess the efficiency of treatments in patients with localized prostate cancer, by
synthesizing available evidence from European economic evaluations through systematic review.
Methods: Articles published 2000–2015 were searched in MEDLINE, EMBASE and NHS EED (Prospero protocol
CRD42015022063). Two authors independently selected studies for inclusion and extracted the data. A third
reviewer resolved discrepancies. We included European economic evaluations or cost comparison studies, of any
modality of surgery or radiotherapy treatments, regardless the comparator/s. Drummond’s Checklist was used for
quality assessment.
Results: After reviewing 8,789 titles, 13 European eligible studies were included: eight cost-utility, two cost-
effectiveness, one cost-minimization, and two cost-comparison analyses. Of them, five compared interventions with
expectant management, four contrasted robotic with non robotic-assisted surgery, three assessed new modalities of
radiotherapy, and three compared radical prostatectomy with brachytherapy. All but two studies scored ≥8 in the
quality checklist. Considering scenario and comparator, three interventions were qualified as dominant strategies
(active surveillance, robotic-assisted surgery and IMRT), and six were cost-effective (radical prostatectomy, robotic-
assisted surgery, IMRT, proton therapy, brachytherapy, and 3DCRT). However, QALY gains in most of them were
small. For interventions considered as dominant strategies, QALY gain was 0.013 for active surveillance over radical
prostatectomy; and 0.007 for robotic-assisted over non-robotic techniques. The highest QALY gains were 0.57–0.86
for radical prostatectomy vs watchful waiting, and 0.72 for brachytherapy vs conventional radiotherapy.
Conclusions: Currently, relevant treatment alternatives for localized prostate cancer are scarcely evaluated in
Europe. Very limited available evidence supports the cost-effectiveness of radical prostatectomy over watchful
waiting, brachytherapy over radical prostatectomy, and new treatment modalities over traditional procedures.
Relevant disparities were detected among studies, mainly based on effectiveness. These apparently contradictory
results may be reflecting the difficulty of interpreting small differences between treatments regarding QALY gains.
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Prostate cancer is the second most common cancer in
men. An estimated 1.1 million men worldwide were diag-
nosed in 2012, with 345,000 cases in the European Union
[1]. Estimates of public health expenditure on cancer indi-
cate that prostate was the third contributor (6 % of the
total), after colorectal and breast tumours [2]. Furthermore,
United States (US) projections for the 2010–2020 period
indicate a 27 % increase in cancer medical costs, where the
largest is the continuing care phase of prostate cancer
(42 %) [3].
Currently, most of the patients diagnosed (94 %) have
localized prostate cancer [4] (ie, stage T1 or T2), and the
number of treatments continues to increase [5, 6]. Despite
the similar proven efficacy in terms of overall survival [7],
these treatments differ substantially in their side effects
pattern [8–11]. With so many different alternatives, health
economics may contribute with relevant information for
decision-making on treatment for localized prostate can-
cer [12], and there has been an increasing number of eco-
nomic evaluations worldwide: comparing surgery versus
radiotherapy [13, 14], different variations of prostatectomy
[13, 15–17] or radiotherapy [13, 14, 18–21].
The National Institute for Clinical Excellence (NICE)
published a global systematic review of economic evalua-
tions for localized prostate cancer treatments in 2003
[22], before the new surgical and radiotherapy modalities
appeared. Since, only two other systematic reviews have
been published on economic evaluations. One, focusing
on radiotherapy [23], identified 14 studies. The other
one, evaluating radical prostatectomy, did not identify
any complete economic evaluation meeting inclusion
criteria, but instead included 11 cost comparison stud-
ies [24]. To our knowledge, there is no global system-
atic review that takes into account the economic
evaluations of all treatments published during the last
15 years, including those comparing different therapies,
such as radical prostatectomy versus radiotherapy or
active surveillance. As a consequence, the efficiency of
existing treatment options for localized prostate cancer
is still uncertain.
Most of the economic evaluations were conducted in
the US [23–26], yet differences in health systems across
countries limit their results’ generalizability. Although
there are also important differences within European
countries, they share some major principles (such as a
mainly publicly funded and almost universal coverage)
far away from the insurance-based US health care system.
Since economic evaluations are relevant to local context,
our interest was centered in those performed in Europe.
The aim of this study was to assess the efficiency of treat-
ments in patients with localized prostate cancer, by syn-
thesizing the available evidence from European economic
evaluations through systematic review.Methods
The protocol was registered in PROSPERO (http://
www.crd.york.ac.uk/Prospero) with number CRD42015
022063. We conducted systematic searches in MED-
LINE, EMBASE and NHS EED (NHS Economic Evalu-
ation Database, CRD York) databases with a specific
strategy (see online Additional file 1) from January 1st
2000 to December 31st 2015.
We looked for economic evaluations (cost minimization,
cost-effectiveness, cost-utility, and cost-benefit analyses) or
cost comparison studies that assessed any modality of sur-
gery or radiotherapy treatments, regardless of the compara-
tor/s, for patients with localized prostate cancer (T1–T2).
Articles were considered when referring to any European
country, and published in any European language.
Studies were excluded if they only performed cost esti-
mations without comparing treatments (such as cost
studies, cost of illness studies, or budget impact ana-
lyses); they were not primary studies (reviews, editorials
or commentaries); they assessed patients with advanced
prostate cancer; or they evaluated diagnosis or screening
procedures, but no treatments.
Two members of the study team (JJ and VB) inde-
pendently reviewed articles found in the literature search
by examining them in three consecutive phases: titles,
abstracts, and full text. A third reviewer (MA) resolved
discrepancies. A pilot test was performed to homogenize
criteria among reviewers. Finally, the reference lists of
the selected articles and those of previous systematic re-
views were reviewed to identify other possible studies
that could be included. Coding for inclusion and exclu-
sion criteria were defined and recorded for each stage.
Assessment of studies’ quality and data extraction was
performed by the consensus of two reviewers (VB and
MA). Drummond’s Checklist was used for quality assess-
ment [27]. Data was extracted using a standardized, pre-
piloted data collection form, including participant charac-
teristics, interventions, comparator, economic perspective,
and time horizon among others. The pre-defined primary
outcome to be extracted was the incremental cost per
Quality-Adjusted Life-Year (QALY) gained. Other Incre-
mental Cost-Effectiveness Ratios (ICERs) and comparative
costs per treatment were considered secondary outcomes.
For illustrative purposes a figure has been designed to show
all estimations of accumulated cost converted into euros
(considering the current 2015 exchange rates), and plotted
them through the time horizon for each intervention. Pa-
tient Intervention Comparator Outcome (PICO) strategy
for this review is shown in the online Additional file 2.
Results
Literature flow in the systematic review
Figure 1 shows the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow of Literature Diagram
Becerra et al. BMC Health Services Research  (2016) 16:541 Page 3 of 13diagram. Once 1,271 duplicates were excluded, 8,789
titles and 1,367 abstracts were reviewed, 165 articles
were fully read, and finally only 13 eligible studies
were included. Overall agreement and kappa coeffi-
cients (k) between reviewers were 79.7 % (k = 0.35),
92.8 % (k = 0.63), and 88.3 % (k = 0.53) in the title, ab-
stract, and full text stages, respectively.
Characteristics of economic evaluations identified in the
systematic review
Table 1 shows the characteristics of the 13 economic evalu-
ations which met the inclusion criteria [22, 28–39]. Most
were conducted in the United Kingdom (UK), Sweden, and
France. All were complete economic evaluations, except
two cost-comparisons [30, 34]: eight were cost-utility ana-
lyses, two cost-effectiveness analyses [31, 39] and one cost-
minimization analysis [38]. Studies were classified accord-
ing to the treatments they evaluated: a) in five studies [22,
28–31] interventions were compared with expectant
management (watchful waiting or active surveillance);
b) four studies compared robotic-assisted laparoscopic
prostatectomy with other surgical techniques [32–35];
c) three studies contrasted conventional externalradiotherapy with new modalities [22, 36, 37] (Inten-
sity-Modulated Radiation Therapy–IMRT, proton ther-
apy and brachytherapy); and d) three studies compared
radical prostatectomy with radiotherapy [22, 38, 39].
Only the 2003 Hummel et al. study [22] provided data
for more than one of these classification groups (a, c
and d).
Most of the evaluations (nine out of 13) were con-
ducted from a payer’s perspective. Regarding the time
horizon, lifetime (assuming an age limit of 100 years)
was considered in five studies [22, 28, 32, 36, 37], one
decade in three other studies [29, 30, 33], and shorter
periods for the rest (from hospital stay to 5 years).
Source of cost was medical records from study co-
horts, such as the Scandinavian Prostatic Cancer
Group Study Number 4 (SPCG-4) [40], or national
database registers of activities such as the British Na-
tional Health System (NHS) or, more rarely, only lit-
erature review (two studies) [36, 37]. Similar sources
were used for effects on health. Only in seven studies
the threshold to consider an alternative as cost-
effective was clearly stated [28, 29, 32, 33, 36, 37, 41].
It ranged from €20,000 to €55,000 per QALY gained,
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Table 2 Main findings of economic evaluations identified in the systematic review
Authors (Year)
Country
[Reference]
Mean Cost
Mean Incremental (Δ)
Cost
Effectiveness
measure or
Incremental (Δ)
QALYs
ICER Sensitivity Analyses Conclusions
A. Expectant management (active survaillance or watchful waiting) vs other treatments
Koerber, et al. (2014)
[28]
Mean Cost:
RP €16468; AS €9585
Mean Δ Cost RP vs AS:
€6883
Life expectancy:
RP 12.15; AS 12.07
QALYs:
RP 7.56; AS 7.60
€/Life year gained
for RP: 96420
€/QALY gained:
AS resulted a
dominant strategy
over RP.
-Probability of
metastases in AS
-AS utility weights
-Time horizon: 5, 15
and 30 years.
-Discount rate 0,5,7
and 10 %
“AS is likely to be a cost-saving
treatment strategy for some
patients with early stage local-
ized prostate cancer. However,
cost-effectiveness is dependent
on patients’ valuation of health
states […]”
Lyth, et al. (2012)
[29]
Mean Δ Cost RP vs WW:
S1-SEK 40116
S2-SEK 49784
S3-SEK 59160
S4-SEK 63834
S5-SEK 70074
S6-SEK 72439
Δ QALY:
S1-0.57
S2-0.86
S3-0.25
S4-0.42
S5-0.08
S6-0.15
SEK/QALY gained for
RP:
S1-70766
S2-58045
S3-232409
S4-150274
S5-858703
S6-472327
Scenarios:
S1-65y Gleason 0–4
S2-65y Gleason 5–6
S3-70y Gleason 0–4
S4-70y Gleason 5–6
S5-75y Gleason 0–4
S6-75y Gleason 5–6
“Assuming a threshold value of
200000 SEK/QALY gained, for
patients aged ≤70 years the
treatment is always cost-
effective, except at age 70,
Gleason 0–4 and PSA ≤10
[…]”
Andersson, et al. (2011)
[30]
Mean Cost:
RP €24247; WW €18124
Not Applicable Not Applicable Not Applicable “In this economic evaluation
of RP versus WW of localized
prostate cancer in a
randomized study, RP was
associated with 34 % higher
costs. […]”
Bauvin, et al. (2003)
[31]
Mean Cost:
RP €8533; WW €2143
5 year survival:
RP 89 %; WW 78 %
5 year relative
survival:
RP 97 %; WW 95 %
ICER not reported Not reported Results supported the cost-
effectiveness of radical pros-
tatectomy over watchful
waiting.
Hummel, et al. (2003)
[22]
Mean Cost:
WW £1714
BT £6880
3DCRT £2103
QALYs:
WW 8.88
BT 9.28
3DCRT 8.89
£/QALY gained (WW
as reference):
-12828 for BT
-26766 for 3DCRT
-Incidence of
adverse events
-Utilities
-Age
-Costs
“[…] It is difficult therefore to
draw conclusions on the
relative benefits or otherwise
of the newer technologies
owing to the lack of
substantive evidence of any
quality and the lack of
comparisons between the
newer technologies and with
standard treatments. […]”
B. Robot-assisted laparoscopic prostatectomy (RALP) vs other surgical techniques
Lord, et al. (2013)
[32]
Mean Costs:
RRP £6485; LRP £6534
PRP £6510; RALP £6458
QALYs:
RRP 7.937; LRP 7.936
PRP 7.936; RALRP
7.943
£/QALY gained:
RALP resulted a
dominant strategy
over all other
-Willingness-to-pay
threshold
“[…] The practical usefulness
of our models to guideline
developers and users should
also be investigated, as
should the feasibility and
usefulness of whole
guideline modelling
alongside development of a
new Clinical Guidelines.”
Close, et al. (2013)
[33]
Mean Costs:
RALP £9040; LRP £7628
N° Procedures/year (P/
year)
200 RALP £9040; LRP
£7628
150 RALP £9799; LRP
£7628
100 RALP £11312; LRP
£7628
QALYs:
RALP 6.52; RLP 6.44
£/QALY gained for
RALP:
-18329 for 200 P/year
-28172 for 150 P/year
-47822 for 100 P/year
-106839 for 50 P/year
Three-arm robot
(DaVinci®)) £7009/
QALY for 200 P/year
-Positive margin rate
after RALP
-Procedures/year
-Patient’s lifetime
-Price of robotic
system
“Higher costs of robotic
prostatectomy may be offset
by modest health gain
resulting from lower risk of
early harms and positive
margin, provided >150 cases
are performed each year.
Considerable uncertainty
persists in the absence of
directly comparative
randomised data.”
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Table 2 Main findings of economic evaluations identified in the systematic review (Continued)
50 RALP £15859; LRP
£7628
Three-arm robot (Da
Vinci®) with 200 P/year:
RALP £8168; LRP £7628
Barbaro, et al. (2012)
[34]
Mean Surgical Costs:
RALP €20103; RRP €2764
Mean Hospital Costs:
RALP €3358; RRP €2791
Mean Total Costs:
RALP €23610; RRP €5635
Not Applicable Not Applicable -Case volumes
-Operating times
” In the current
circumstances, increasing the
use of RAP at the San
Giovanni Battista Hospital
does not appear expedient.
This conclusion is
corroborated by the
sensitivity analysis which
showed that RAP carries
higher costs than RRP.”
Hohwu, et al. (2011)
[35]
Mean direct costs:
RALP €8369
RRP €3863
Mean Indirect costs:
RALP €13411
RRP €12465
Successful treatment:
RALP 34 %; RRP
27 %
Δ QALYs:
RALP 0.0103; RRP
0.0116
€/extra successful
treatment for RALP
-64343 for direct
costs
-13514 for indirect
costs
€/QALY gained for
RALP:
Not applicable
because no QALY
gained
-Life time for robot
-Procedures/year
“RALP was more effective
and more costly. A way to
improve the cost
effectiveness may be to
perform RALP at fewer high
volume urology centres and
utilise the full potential of
each robot”
C. Conventional external radiotherapy vs new modalities
Hummel, et al. (2012)
[36]
Mean total discounted
costs:
IMRT/3DCRT
S1-£6173/£5184
S2-£4946/£4214
S3-£4946/£4486
S4-£5687/£7489
Total discounted
QALY:
IMRT/3DCRT
S1-6.802/6.792
S2-7.070/7.046
S3-7.070/6.983
S4-7.015/6.402
£/QALY gained for
IMRT:
S1-104066
S2-31162
S3-5295
S4-dominant
strategy.
Scenarios:
S1-equal dose& PSA
relapse
S2-15 % difference
in late gastro
intestinal toxicity
S3-3.8 y survival
difference
S4-6.6 y survival
difference
“If IMRT can be used to
prolong survival, it is very
cost-effective. Otherwise
cost-effectiveness is
uncertain”
Lundkvist, et al.
(2005)
[37]
Δ total cost for standard
case
Proton Therapy vs
External Radiotherapy:
€7953 per patient,
Δ QALY for Proton
Therapy: 0.297/
patient
€/QALY gained for
Proton Therapy:–
26776
Not reported “Proton therapy was cost-
effective if appropriate risk
groups were chosen. The re-
sults must be interpreted
with caution, since there is a
lack of data, and conse-
quently large uncertainties in
the assumptions used”
Hummel, et al. (2003)
[22]
Mean total costs:
2DRT £1886
BT £6880
3DCRT £2103
QALYs:
2DRT 8.56
BT 9.28
3DCRT 8.89
£/QALY gained
(2DRT as reference):
-8575 for BT
-683 for 3DCRT
-Incidence of
adverse events
-Utilities
-Age
-Costs
See above
D. Prostatectomy vs radiation treatment
Becerra, et al. (2011)
[38]
Mean total cost:
RP €6863.70
BT €5453.60
3DCRT €3336.10
Not Applicable Not Applicable -Cost of 3DCRT “Radical prostatectomy
therapeutic proved to be the
most expensive treatment
option. […] Most of the costs
were explained by the
therapeutic option, and
neither comorbidity nor risk
groups showed an effect of
total costs independent of
treatment.”
Buron, et al. (2007)
[39]
Mean societal cost:
BT €8019; RP €8715
Urinary incontinence
BT 20 %; RP 49 %
Fecal incontinence
ICER not reported Not reported “This study suggests a similar
cost profile in France for BT
and RP but with different
Becerra et al. BMC Health Services Research  (2016) 16:541 Page 7 of 13
Table 2 Main findings of economic evaluations identified in the systematic review (Continued)
Mean Initial treatment
costs:
BT €7159; RP €6472
Mean hospital follow-up
costs:
BT €268; RP €992
Mean Outpatient costs:
BT €482; RP €419
Mean loss productivity
costs:
BT €620; RP €3678
BT 9 %; RP 2 %
Rectal Bleeding
BT 15 %; RP 0 %
Erectile Dysfunction
BT 45.8 %; RP 83.3 %
health-related quality of life
and side effect profiles. Those
findings may be used to
tailor localized prostate can-
cer treatments to suit individ-
ual patients’ needs.”
Hummel, et al. (2003)
[22]
Mean total costs:
RP £6359
BT £6880
3DCRT £2103
QALYs
RP 8.93
BT 9.28
3DCRT 8.89
£/QALY gained (RP
as reference):
-12828 for BT
-Not Applicable
- Incidence of
adverse events
-Utilities
-Age
-Costs
See above
Abbreviations: AS Active Surveillance, BT Brachytherapy, ICER Incremental Cost-Effectiveness Ratio, IMRT Intensity-Modulated Radiation Therapy, LRP Laparoscopic
Prostatectomy, RALP Robot-Assisted Laparoscopic Prostatectomy, RP Radical Prostatectomy, PRP Perineal Radical Prostatectomy, RRP Radical Retropubic Prostatec-
tomy, QALYs Quality-Adjusted Life Years, WW Watchful Waiting, 2DRT Two Dimensional Radiotherapy, 3DCRT Three Dimensional Conformal Radiotherapy
Fig. 2 Estimations of accumulated direct costs (euros) for each
intervention plotted through the time horizon (years). Numbers
correspond to the articles in the reference list. Abbreviations: RALP:
robot-assisted laparoscopic prostatectomy; RP: radical prostatectomy;
IMRT: intensity-modulated radiation therapy; ERT: external radiation
therapy; BT: brachytherapy; EM: expectant management
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this threshold [22, 28, 32, 33].
Main findings of economic evaluations identified in the
systematic review
Estimated total direct cost for every treatment alterna-
tive was reported in all but two of the studies (see
Table 2), which only showed incremental cost difference
[29, 37]. Eight studies could provide incremental cost
per QALY gained [22, 28, 29, 32, 33, 35–37], and four
studies other outcomes such as life year gained [28], 5-
year survival [31], successful treatment [35], and treat-
ment side effects [39].
Of the interventions evaluated, three were found to be
not only cost-effective but also dominant strategies
(more effective and less costly): active surveillance over
radical prostatectomy from a societal perspective in
Germany [28], robotic-assisted over non-robotic surgical
techniques [32], and IMRT over 3-Dimensional Con-
formal Radiation Therapy (3DCRT) when assuming a
survival improvement of 6.6 years [36]. The following
six interventions were found to be cost-effective: radical
prostatectomy over watchful waiting in patients aged 70
or younger [29], robotic-assisted over non-robotic lap-
aroscopic radical prostatectomy if more than 150 proce-
dures performed per year [33], IMRT over 3DCRT when
survival improvement is ≥3.8 years [36], and proton
therapy [37], brachytherapy [22] and 3DCRT [22] over
conventional radiotherapy. Conversely, the highest cost
per QALY gained (least efficient options) were shown for
radical prostatectomy versus watchful waiting in patients
older than 75 [29], robotic-assisted versus non-robotic
radical prostatectomy performing 50 procedures per year
[33] (over £100,000), and for IMRT versus 3DCRT at
equal doses and same survival to Prostate-Specific Anti-
gen (PSA) progression [36] (over €100,000).Estimations of accumulated direct costs in euros were
plotted through the time horizon in Fig. 2 for each inter-
vention. In total, the figure shows 38 estimates reported by
11 studies. The lowest costs (around €2,000) were obtained
for expectant management (specifically, watchful waiting)
at time horizons of 5 years and lifetime, as reported by
Bauvin et al. [31] and Hummel et al. [22], respectively. The
highest costs (around €24,000) were obtained for robotic-
assisted surgery during hospitalization [34] and for radical
prostatectomy at 12 years [30].
Quality of the economic evaluations identified in the
systematic review
The quality of the studies according to Drummond’s 10-
item checklist is illustrated in Table 3. From the 11 eco-
nomic evaluations, nine studies scored ≥8 points. The
item that most frequently failed was about effectiveness,
appraised uncertain or negative in six studies.
Table 3 Methodological quality assessment of economic evaluations using Drummond’s 10-item checklist
(Yes/no/can’t tell) Koerber
[28]
Lyth
[29]
Bauvin
[31]
Hummel
[22]
Lord
[32]
Close
[33]
Hohwu
[35]
Hummel
[36]
Lundkvist
[37]
Becerra
[38]
Buron
[39]
1. Was a well-defined question posed in
answerable form?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
2. Was a comprehensive description of the
competing alternatives given (i.e. can you
tell who did what to whom, where, and
how often)?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
3. Was the effectiveness of the programme
or services established?
Can’t
Tell
Can’t
Tell
Yes No Can’t
Tell
Yes Yes Yes Can’t Tell No Yes
4. Were all the important and relevant costs
and consequences for each alternative
identified?
Yes Yes Yes Yes Yes Yes Yes Yes Can’t Tell Yes Yes
5. Were costs and consequences measured
accurately in appropriate physical units’
Yes Yes No Yes Yes Yes Yes Yes Can’t Tell Yes Yes
6. Were costs and consequences valued
credibly?
Yes Yes Can’t
Tell
Yes Yes Yes No Yes Can’t Tell Yes Yes
7. Were costs and consequences adjusted
for differential timing?
Yes Yes Yes Yes Yes Yes No Yes Yes No No
8. Was an incremental analysis of costs and
consequences of alternatives performed?
Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes
9. Was allowance made for uncertainty in
the estimates of costs and consequences?
Yes Yes No Yes Yes Yes Yes Yes No Yes Yes
10. Did the presentation and discussion of
study results include all issues of
concern to users?
Yes Yes Can’t
Tell
Yes Yes Yes Yes Yes Can’t Tell Yes Yes
Score (Total) 9 9 5 9 9 10 8 10 4 8 9
Number between square brackets corresponds to reference list position
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Our systematic literature review identified 13 European
studies, published 2000–2015, which conducted either
economic evaluations or cost comparisons (11 and two,
respectively) of any modality of surgical or radiotherapy
treatments for localized prostate cancer patients. These
studies varied widely in compared alternatives, costing
methodologies, and time horizon. Estimations of incre-
mental cost per QALY gained were provided by eight
studies. Depending on the scenario and the comparator
considered, three interventions were qualified as domin-
ant (active surveillance [28], robotic-assisted surgery
[32], and IMRT [36]), and six as cost-effective (radical
prostatectomy [29], robotic-assisted surgery [33], IMRT
[36], proton therapy [37], brachytherapy [22] and
3DCRT [22]).
Expectant management (active surveillance or watchful
waiting) vs other treatments
Two cost-utility analyses comparing radical prostatectomy
with expectant management show contradictory results:
Koerber et al. [28] found that active surveillance was the
dominant alternative (more QALYs at less cost), while Lyth
et al. [29] showed that radical prostatectomy was more
cost-effective than watchful waiting. However, the gain in
QALYs in favor of active surveillance was extremely small(0.013) [28], and moderate-to-small in favor of radical pros-
tatectomy (0.57–0.86) [29]. On the other hand, differences
in the comparator used in both studies (active surveillance
[28] and watchful waiting [29]) could also partly explain
this disparity. No immediate treatment was performed in
watchful waiting patients [29], while active surveillance in-
volved [28] monitoring with PSA, digital rectal examin-
ation, and biopsy. Consistent with results reported by Lyth
et al. [29], the cost-effectiveness study by Bauvin et al. [31]
showed that radical prostatectomy is more effective than
watchful waiting. Unfortunately, although the economic
evaluation of Hummel et al. [22] also evaluated radical
prostatectomy, they did not report its comparison with
watchful waiting.
Robot-assisted laparoscopic prostatectomy (RALP) vs
other surgical techniques
The previous systematic review of economic evaluations
comparing robotic-assisted vs non-robotic laparoscopic
surgery [24] proved to be insufficient for decision making,
leading the authors to build a de novo economic evaluation
[33], which has been now included in our review. Two of
the three cost-utility studies that we identified consistently
support the cost-effectiveness of robotic-assisted surgery
[32, 33]. Lord et al. [32] showed that robotic-assisted tech-
nique is the dominant alternative among surgery, while
Becerra et al. BMC Health Services Research  (2016) 16:541 Page 10 of 13Close et al. [33] estimated a cost of £18,329 per QALY
gained. Hohwu et al. [35] found no QALY gain for robotic-
assisted surgery, but the authors underlined the uncertainty
of their QALY estimates due to a high degree of missing
data. Again, disparity among these economic evaluations is
mainly due to contradictory results on effectiveness, which
were based on extremely small QALY gains for the robotic-
assisted technique: 0.007 reported by Lord et al. [32], and
0.08 by Close et al. [33] In fact, current guidelines of the
European Association of Urology [5, 6] consider all ap-
proaches (i.e., open, laparoscopic, and robotic) as acceptable
for patients who are surgical candidates, because no single
modality has shown a clear superiority in terms of func-
tional or oncological results. On the other hand, it is im-
portant to highlight that the recommendation of the NICE
Clinical Guideline [42] to provide robots in centers with an
expected performance of at least 150 robotic-assisted oper-
ations per year, is only based on the economic evaluation
published by Close et al. [33] It would be advisable to con-
firm this recommendation with future specific studies to
help decision makers.
Conventional external radiotherapy vs new modalities
The systematic review of cost-effectiveness analysis by
Amin et al. [23], comparing different radiation treatments,
identified 14 studies (most from the United States, and
only two from Europe [22, 36]). Although evidence sug-
gested that brachytherapy and IMRT were more cost-
effective than external beam radiotherapy, the authors
highlighted the uncertainties and variation among studies
[23]. We only identified three European economic evalua-
tions comparing radiation therapies, each focusing on a
different new modality (IMRT [36], proton therapy [37],
and brachytherapy [22]). The three showed to be more
cost-effective than conventional radiotherapy. However,
each of these findings came from only one study, so fur-
ther research is needed to confirm them. Once again, it is
important to point out that the magnitude of the QALY
gains is small for scenarios evaluating IMRT (0.01–0.613)
[36] or proton therapy (0.297) [37], and moderate-to-
small in favor of brachytherapy (0.72) [22]. The European
Association of Urology guidelines (5) recommend IMRT
for definitive treatment with external radiotherapy, and
brachytherapy for patients fulfilling specific criteria (low
risk, prostate volume below 50 mL, no urinary obstruc-
tion, and no previous transurethral resection).
Prostatectomy vs radiation treatment
Of the three studies comparing prostatectomy with radi-
ation treatment, only Hummel et al. [22] published a
cost-utility analysis showing that brachytherapy was
more cost-effective than surgery, with an incremental
cost of €2,021–2,760 per QALY gained. Buron et al. [39]
did not calculate ICERs but showed similar societal costsbetween radical prostatectomy and brachytherapy,
though different treatment side effects: radical prostatec-
tomy caused higher rates of urinary incontinence and
erectile dysfunction, while brachytherapy presented irri-
tative urinary and bowel symptoms more frequently.
These results are consistent with the well-known side ef-
fect profiles of these treatments [8–11]. The cost-
minimization published by Becerra et al. [38] assumed
equal effectiveness in terms of survival, but did not take
into account other relevant outcomes such as relapses
and treatment side effects. Thus, evidence supporting
the cost-effectiveness of brachytherapy over open radical
prostatectomy originates from one single study [22]
showing a small QALY gain (0.35), and there are no eco-
nomic evaluations comparing brachytherapy with
robotic-assisted surgery.
Accumulated direct costs per treatment
As shown in Fig. 2, the cost-comparison study per-
formed in Sweden reported the highest estimation of
costs for radical prostatectomy and watchful waiting
(€24,247 and €18,124) [30]; also, the cost-comparison
study published by Barbaro et al. [34] showed an ex-
treme perioperative cost in an Italian hospital for robotic
surgery (€23,610). The high cost estimated in these two
empirical cost-comparison studies [30, 34] (based on the
observation of health care activities in real cohorts)
could indicate underestimation of real costs when they
are based on models from theoretical cohorts. Further-
more, the surprisingly low accumulated costs estimated
in most studies with theoretical cohorts and lifetime
horizon [22, 32, 36], similar or even lower than those re-
ported for studies with a shorter time horizon [31, 33],
also suggest an underestimation of real costs in these
studies.
Cost and effectiveness components
Economic evaluations have two components. Regarding the
cost component, it is important to highlight the similarities
of the new treatment modalities compared with the trad-
itional techniques, such as robotic versus non-robotic sur-
gery [33] and IMRT versus external beam radiotherapy
[36], when provided under rational conditions. Besides
watchful waiting, the cheapest, all other treatments seem to
be quite similar: most have an equivalent total cost below
€17,000. The European estimates of accumulated direct
healthcare costs identified are much lower than those re-
ported in US. For instance, Cooperberg et al. [13] consider-
ing lifetime, and Hayes et al. with a 10 year horizon [14]
reported costs figures of: $20,000–38,000 in radical prosta-
tectomy; around $33,000 in 3DCRT; $38,000–54,000 in
IMRT; or $25,000–44,000 in brachytherapy. Different
health systems and cost structures between US and Europe
may explain these variances.
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ever, the aforementioned disparities among studies in
the identification of the most effective treatment may re-
flect the misinterpretation of such small QALY gains
showed by the majority of them. For example, the gain
of 0.013 QALYs [28] was much too small to consider ac-
tive surveillance the dominant strategy over radical pros-
tatectomy; or the gain of 0.007 QALYs [32] to consider
robotic-assisted the dominant strategy over non-robotic
techniques. Even the clinical relevance of the highest
QALY gains identified in this review (0.57–0.86 for rad-
ical prostatectomy vs watchful waiting [29], and 0.72 for
brachytherapy vs conventional radiotherapy [22]) may be
questionable to be interpreted as relevant differences on
effectiveness. Which is the reasonable cut-off for consid-
ering one intervention more effective than its alterna-
tive? Could gains lower than one QALY through
10 years or lifetime be considered clinically significant?
Results from US economic evaluations [13, 14] also
showed no relevant differences in QALY gains for life-
time across treatments: ranging 0.5–1 or 0.7–0.8 for pa-
tients at low and intermediate risk, respectively, when
comparing surgical and radiation therapies [13]; 0.9, 0.9,
and 1.1 when comparing brachytherapy, IMRT and sur-
gery with watchful waiting [14]. The clinical relevance of
less than 1 year benefits between alternatives (in time
horizons > 10 years of life) is questionable, and common
sense prevents from interpreting them as differences in
effectiveness.
An important issue related to the generalizability of
study findings is the cost-effectiveness threshold, which
represents society’s willingness-to-pay for an additional
unit of benefit [26]. Studies from UK showed a very con-
sistent pattern regarding this threshold: they considered
NICE’s thresholds of £20,000–£30,000 per QALY gained
[22, 32, 33, 41]. Sweden studies showed a wider range
for this threshold, from 200,000 SEK (€21,000) [29] to
€55,000 per QALY gained [37]. The latter was very simi-
lar to the threshold applied in the German study
(€50,000 per QALY gained) [28]. None of them was far
from the US threshold’s commonly accepted standard of
$50,000 per QALY gained.
Limitations of the systematic review
There are several limitations that may affect our review
findings. First, we cannot be sure that no relevant study
is missing from this systematic review. However, in order
to find as many relevant studies as possible, we have per-
formed the search in PubMed and EMBASE, the most
comprehensive databases in health sciences, as recom-
mended [43], as well as in a specific database for eco-
nomic evaluations. In addition, we designed a very
sensitive search strategy (yielding the 8,789 titles revised)
and we performed an additional manual referencesearch. Second, no quantitative synthesis of the results
by meta-analysis was planned due to the well-known
high heterogeneity among health economic evaluations.
Furthermore, considering the scarce number of studies
comparing the same interventions, obtaining a pooled
estimator would make no sense. Third, internal validity
of the synthesis provided by a systematic review depends
on the quality of primary studies. In our systematic re-
view, quality could be considered good except for effect-
iveness, which failed in almost half of the studies. It is
necessary to take into account that recruitment for ran-
domized trials presented considerable difficulties in
these patients [44, 45], and the only available trial, the
SPCG-4 [40]–which was used in several of these eco-
nomic evaluations, was conducted at the beginning of
PSA era. Fourth, studies with a cost-comparison design
were included despite not being economic evaluations.
However, the information they provided clearly contrib-
uted to the amount and robustness of evidence on costs.
Finally, Fig. 2 shows reported direct healthcare costs
without transforming them into a single year to avoid
manipulation. We only converted currency into euros,
using 2015 exchange rates, to facilitate comparisons.
Conclusions
To our knowledge, this is the first systematic literature
review of the European economic evaluations of all main
primary treatments for localized prostate cancer pub-
lished during the last 15 years. The 13 studies identified
(five comparing interventions with expectant manage-
ment, four contrasting robotic with non-robotic assisted
surgery, three assessing new modalities of radiotherapy,
and three comparing radical prostatectomy with brachy-
therapy) showed that currently relevant treatment alter-
natives for localized prostate cancer are scarcely assessed
in economic evaluations in the European countries. Fur-
thermore, differences between cost-comparison and
cost-effectiveness studies suggest underestimation of
costs in studies based on models from theoretical
cohorts.
In conclusion, very limited evidence supports the cost-
effectiveness of radical prostatectomy versus watchful wait-
ing, and that of brachytherapy versus radical prostatectomy.
Regarding the evaluation of new treatment modalities, also
limited evidence supports the cost-effectiveness of robotic-
assisted laparoscopic radical prostatectomy versus non-
robotic procedures, and that of brachytherapy, IMRT and
proton therapy versus traditional external radiotherapy.
Relevant disparities were detected among studies, mainly
based on effectiveness. These apparently contradictory re-
sults may be reflecting the difficulty of interpreting small
differences between treatments regarding QALY gains.
Moreover, despite an acceptable methodological quality in
most aspects of the studies included, the effectiveness
Becerra et al. BMC Health Services Research  (2016) 16:541 Page 12 of 13uncertainty could jeopardize the internal validity of their
results.
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